{
  "id": "58dbb3f18acda34529000019",
  "type": "list",
  "question": "Which are the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) inhibitors that are FDA approved?",
  "ideal_answer": "The PCSK9 inhibitors that are FDA approved are:\n1) Alirocumab and \n2) Evolocumab.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26548330",
    "http://www.ncbi.nlm.nih.gov/pubmed/27086681",
    "http://www.ncbi.nlm.nih.gov/pubmed/26785741",
    "http://www.ncbi.nlm.nih.gov/pubmed/27533159",
    "http://www.ncbi.nlm.nih.gov/pubmed/27661220",
    "http://www.ncbi.nlm.nih.gov/pubmed/26345307",
    "http://www.ncbi.nlm.nih.gov/pubmed/26445204",
    "http://www.ncbi.nlm.nih.gov/pubmed/26822080",
    "http://www.ncbi.nlm.nih.gov/pubmed/26798848",
    "http://www.ncbi.nlm.nih.gov/pubmed/27567901",
    "http://www.ncbi.nlm.nih.gov/pubmed/26652782",
    "http://www.ncbi.nlm.nih.gov/pubmed/26886466",
    "http://www.ncbi.nlm.nih.gov/pubmed/27207595",
    "http://www.ncbi.nlm.nih.gov/pubmed/26596726",
    "http://www.ncbi.nlm.nih.gov/pubmed/23889692",
    "http://www.ncbi.nlm.nih.gov/pubmed/27186592",
    "http://www.ncbi.nlm.nih.gov/pubmed/26968977"
  ],
  "snippets": [
    {
      "text": "Inhibition of the PCSK9 protein by monoclonal antibodies results in a dramatic 40%-60% lowering of serum low-density lipoprotein cholesterol (LDL-C). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26822080",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Alirocumab and evolocumab have been approved by the FDA for the treatment of patients with heterozygous familial hypercholesterolemia and patients with clinical atherosclerotic cardiovascular disease) who do not achieve their LDL-C target on maximal tolerated statin treatment and dietary modification. In addition, evolocumab has been approved by the FDA for homozygous familial hypercholesterolemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26822080",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "LDL cholesterol (LDLC) lowering has been revolutionized by PCSK9 inhibitors, Alirocumab (Praluent) and Evolocumab (Repatha), approved as adjuncts to maximally tolerated cholesterol lowering therapy in heterozygous (HeFH) or homozygous (HoFH) familial hypercholesterolemia, and/or clinical atherosclerotic cardiovascular disease (CVD) where LDLC lowering is insufficient.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26968977",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A new class of lipid-lowering drugs, inhibitors of PCSK9 has been generating impressive clinical trial data over the last several years, and alirocumab (Praluent) has become the first to be approved by the US FDA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26785741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The second FDA-approved PCSK9 inhibitor evolocumab (Repatha) appears to be similar in efficacy and safety to alirocumab (Praluent), but no comparative studies are available. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26445204",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hypercholesterolemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27086681",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Newer agents for LDL cholesterol reduction include the cholesterol ester transfer protein inhibitors, the microsomal triglyceride transfer protein inhibitor lomitapide, the apolipoprotein B antisense oligonucleotide mipomersen and several molecules that inhibit or interfere with proprotein convertase subtilisin/kexin 9 (PCSK9).Among the various PCSK9 inhibitors, human data are available for monoclonal antibodies against PCSK9 of which the two most advanced are alirocumab (SAR236553/REGN727) and AMG 145",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23889692",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The 2 or 4\u2011week subcutaneous therapy with the recently approved antibodies alirocumab and evolocumab for inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) reduces low-density lipoprotein cholesterol (LDL-C) in addition to statins and ezetimibe by 50-60\u2009%.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27207595",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In 2015 the U.S. Food and Drug Administration approved the first two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab (Praluent\u00ae; Sanofi/ Regeneron) and evolocumab (Repatha\u00ae; Amgen), for use in patients with heterozygous and homozygous familial hypercholesterolemia and for patients intolerant of statins or those with a major risk of cardiovascular disease (CVD) but unable to lower their LDL cholesterol (LDL-C) to optimal levels with statins and ezetimibe.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Very recent clinical trials have proven overwhelmingly the effectiveness and safety of PCSK9 inhibitors for lowering LDL-C. Both alirocumab and evolocumab have now been approved by the US FDA and there are some initial favorable outcomes data.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26596726",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Food and Drug Administration approved the first two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab (Praluent\u00ae; Sanofi/ Regeneron) and evolocumab (Repatha\u00ae; Amgen), for use in patients with heterozygous and homozygous familial hypercholesterolemia and for patients intolerant of statins or those with a major risk of cardiovascular disease (CVD) but unable to lower their LDL cholesterol (LDL-C) to optimal levels with statins and ezetimibe.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186592",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.uniprot.org/uniprot/PCSK9_MACMU",
    "http://www.uniprot.org/uniprot/PCSK9_PANTR",
    "http://www.uniprot.org/uniprot/PCSK9_COLGU",
    "http://www.uniprot.org/uniprot/PCSK9_CALJA",
    "http://www.uniprot.org/uniprot/PCSK9_SAGLB",
    "http://www.uniprot.org/uniprot/PCSK9_PONPY",
    "http://www.uniprot.org/uniprot/PCSK9_LAGLA",
    "http://www.uniprot.org/uniprot/PCSK9_MACNE",
    "http://www.uniprot.org/uniprot/PCSK9_HUMAN",
    "http://www.uniprot.org/uniprot/PCSK9_ATEGE",
    "http://www.uniprot.org/uniprot/PCSK9_PANPA",
    "http://www.uniprot.org/uniprot/PCSK9_PLEMO"
  ],
  "exact_answer": "Alirocumab, Praluent, Evolocumab, Repatha"
}